PMC:7799377 / 39452-39618 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T264","span":{"begin":0,"end":166},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Third-line strategies for neuroinflammation in COVID patients may carry higher risks, and include such pharmacological agents as cyclophosphamide and rituximab [121]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1372","span":{"begin":53,"end":61},"obj":"Species"},{"id":"1373","span":{"begin":129,"end":145},"obj":"Chemical"},{"id":"1374","span":{"begin":150,"end":159},"obj":"Chemical"},{"id":"1382","span":{"begin":26,"end":43},"obj":"Disease"},{"id":"1383","span":{"begin":47,"end":52},"obj":"Disease"}],"attributes":[{"id":"A1372","pred":"tao:has_database_id","subj":"1372","obj":"Tax:9606"},{"id":"A1373","pred":"tao:has_database_id","subj":"1373","obj":"MESH:D003520"},{"id":"A1374","pred":"tao:has_database_id","subj":"1374","obj":"MESH:D000069283"},{"id":"A1382","pred":"tao:has_database_id","subj":"1382","obj":"MESH:D020078"},{"id":"A1383","pred":"tao:has_database_id","subj":"1383","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Third-line strategies for neuroinflammation in COVID patients may carry higher risks, and include such pharmacological agents as cyclophosphamide and rituximab [121]."}